Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04182425
Other study ID # 2019-A01725-52
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 7, 2019
Est. completion date July 4, 2022

Study information

Verified date March 2023
Source Bledina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study will evaluate the incidence of allergic manifestations (the first of which is atopic dermatitis) and infectious diseases in children fed with an infant formula under real conditions of use.


Description:

The primary objective of the study is to evaluate the cumulative incidence of atopic dermatitis in healthy infants at risk for dysbiosis at 12 months of age and to identify factors associated with the presence of atopic dermatitis.


Recruitment information / eligibility

Status Completed
Enrollment 334
Est. completion date July 4, 2022
Est. primary completion date July 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 5 Weeks
Eligibility Inclusion Criteria: - full-term infant (gestational age = 37 and = 42 weeks) in good health; - Having at least one risk factor for dysbiosis, including: - birth by caesarean section, - Antibiotic exposure between birth and inclusion or in utero (mother who received antibiotics) during the last trimester of pregnancy, or per-partum (mother who received antibiotics during childbirth), - a family history of allergy confirmed by a doctor in a family member, affecting at least one of the two parents or siblings (asthma, atopic dermatitis, eczema, allergic rhinitis, proven food allergy); - Aged at most 5 weeks; - Having a weight in the reference values for gestational age and sex (between the 10th and the 90th percentiles according to the growth curves in force); - Already consuming an infant formula (with or without associated breast milk), or whose mother wishes to introduce an infant formula at the end of this consultation to switch to mixed breastfeeding or to start weaning; - Authorization of a parent (or both) or legal representative of the child to collect personal information about their child and family. Exclusion Criteria: - Premature infants or low birth weight (< 2500g); - Infant allergic to cow's milk protein; - Infants with severe congenital anomalies that may impact growth (cystic fibrosis, bronchopulmonary dysplasia, tracheomalacia, tracheoesophageal fistula, congenital heart defects ...); - Infants with chronic disease or severe neonatal pathology, or a pathology predisposing to infections (HIV, hepatitis B or C, autoimmune diabetes, immune deficiency, respiratory distress, sepsis, intraventricular hemorrhage, severe neonatal hepatitis, necrotizing enterocolitis, hypertension persistent pulmonary ...), or renal or hepatic pathology; - Inability of the parent or legal representative to understand the protocol of the study, or doubts of the physician on the ability or willingness to comply with the protocol.

Study Design


Intervention

Other:
Infant formula
Healthy full-term infants fed on an infant formula marketed on the French market

Locations

Country Name City State
France Medical Office Taverny

Sponsors (1)

Lead Sponsor Collaborator
Bledina

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence of atopic dermatitis in the infants included in the study Number of episodes of dermatitis reported during the 12 months of follow-up, and objectified by a SCORAD score > 0. 12 months
Secondary Atopic dermatitis Cumulative incidence of episodes of moderate atopic dermatitis (SCORAD score of 25 to 50) or severe episodes (SCORAD score> 50) 3, 6 and 12 months
Secondary Gastrointestinal tolerance Frequency, consistency, color and quantity of stool (Amsterdam scale),
Frequency and intensity of regurgitations (adapted score of Vandenplas),
Frequency and intensity of gas / bloating, colic, unexplained crying
3, 6 and 12 months
Secondary Height Growth in term of height 3, 6 and 12 months
Secondary Weight Growth in term of weight 3, 6 and 12 months
Secondary Cranial perimeter Growth in terme of cranial perimeter 3, 6 and 12 months
Secondary Observance % of children who consumed the formula prescribed by the doctor at the previous visit 3, 6 and 12 months
Secondary Consumption Number of days of consumption during the previous period. 3, 6 and 12 months
Secondary Satisfaction with Likert scale 5-level Likert scale filled in by the doctor and by parents 3, 6 and 12 months
Secondary Cumulative incidence of allergic manifestations Cumulative number since the inclusion of episodes of:
atopic dermatitis,
eczema,
wheezing,
allergic rhinitis
3, 6 and 12 months
Secondary Cumulative incidence of infections Cumulative number since the inclusion of episodes of:
Infection of the upper respiratory tract,
Infection of the lower respiratory tract,
Gastrointestinal infections,
pyelonephritis,
3, 6 and 12 months
See also
  Status Clinical Trial Phase
Completed NCT02763345 - The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi N/A
Completed NCT00550706 - Drug Utilization Prevalence in a Pediatric Care Medical Center N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT00761462 - BAY 0 9867 Cipro Pediatric Use Study (QUIP) Phase 3
Completed NCT05088421 - A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers Phase 1
Completed NCT00828971 - A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs Phase 3
Completed NCT05468723 - Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1
Recruiting NCT02162966 - Safety and Efficacy Study of High Dose Colistin Phase 4
Recruiting NCT00001281 - Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
Active, not recruiting NCT02654210 - LoewenKIDS - Infections and the Development of the Immune System
Completed NCT02226263 - Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Phase 2
Terminated NCT00211471 - Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). Phase 2
Active, not recruiting NCT04342702 - A Study on the Prospective Cohort Library of COVID-19 in Southeran
Completed NCT02134548 - Sensitivity Study of Diagnostic for Detection of Chagas Infection N/A
Active, not recruiting NCT01611025 - Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time N/A
Completed NCT01361997 - Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination Phase 3
Completed NCT00638677 - Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier Phase 4
Completed NCT02434848 - A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses Phase 2/Phase 3
Completed NCT02544139 - Specificity Study of Diagnostic for Chagas Disease N/A
Completed NCT00276198 - Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants Phase 3